Compugen Ltd. (CGEN)

1,9800 +0,0900 (+4,76%) Börsenschluss: 04:00PM EDT

Compugen Ltd.

Azrieli Center
Building D 26 Harokmim Street
Holon 5885849
Israel
972 3 765 8585
https://cgen.com

Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 68

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Dr. Anat Cohen-Dayag Ph.D.	CEO, President & Director	796,52k	N/A	1967
Dr. Zurit Levine Ph.D.	Senior Vice President of Technology Innovation	345,7k	N/A	1968
Dr. Pierre Ferre Ph.D.	Vice President of Preclinical Development	415,1k	N/A	1977
Mr. Alberto Sessa	Chief Financial Officer	N/A	N/A	1962
Dr. Eran Ophir Ph.D.	Chief Scientific Officer	N/A	N/A	1978
Ms. Yvonne Naughton	Head of Investor Relations & Corporate Communications	N/A	N/A	N/A
Mr. Eran Ben Dor	General Counsel & Corporate Secretary	N/A	N/A	N/A
Ms. Dorit Amitay	Vice President of Human Resources	N/A	N/A	1968
Dr. Yaron Turpaz M.B.A., Ph.D.	Senior VP & Senior Advisor of Data and Informatics Solutions	N/A	N/A	1971
Rivka Schwartz	Vice President Research and Discovery	N/A	N/A	N/A

Die Beträge haben den Stand 31. Dezember 2022 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in USD.

Beschreibung

Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused to address various mechanisms of immune resistance; and COM503, high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.

Corporate Governance

Compugen Ltd.s ISS Governance QualityScore, Stand N/A, lautet N/A. Die grundlegenden Scores sind Audit: N/A, Vorstand: N/A, Shareholderrechte: N/A, Kompensation: N/A.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.